R Squared’s Cartesian Therapeutics RNAC Stock Holding History

R Squared’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,308	Closed	-$74.3K	–	640
2025 Q4	$74.3K	Buy	+10,308	New	+$83.3K	0.03%	434

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

R Squared's RNAC Position: Q1 2026 in Review

R Squared sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 10,308 shares — an estimated $74.3K sold.

R Squared first reported a position in RNAC in Q4 2025 and held it in 1 quarter. The position peaked at $74.3K in Q4 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

R Squared reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
R Squared sold 10,308 Cartesian Therapeutics shares in Q1 2026, an estimated $74.3K.
R Squared first reported a position in Cartesian Therapeutics in Q4 2025 and held it in 1 quarter.
R Squared's Cartesian Therapeutics position peaked at $74.3K in Q4 2025.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.